奥米替尼异丙酯(一种新型选择性EP2受体激动剂)作为降眼压制剂的药理学特征
本研究通过受体结合与功能试验、兔房水药代动力学及多种动物模型,评估奥米替尼异丙酯(OMDI)及其水解产物奥米替尼(OMD)的药理特性。结果显示OMD为选择性EP2受体激动剂,OMDI滴眼后在房水中仅检测到OMD,且在正常眼压与高眼压动物中均显著降低眼压,每日一次给药即可维持有效时长。
要点
- OMD为选择性EP2受体激动剂,OMDI对EP1结合弱但功能试验未显示激动活性。
- OMDI滴眼后房水中仅检出OMD,未检出OMDI。
- OMDI在正常眼压及高眼压动物中单次和重复给药均显著降眼压,每日一次给药有效。
核心结论
- OMDI在眼内水解为OMD,后者为EP2受体激动剂,在正常眼压和高眼压动物模型中均具有显著降眼压效应。
研究设计与样本
- 研究评估OMDI及其水解产物OMD与人重组前列腺素类受体(DP1-2、EP1-4、FP、IP)的结合活性,并用表达选定受体的培养细胞评估激动活性。
- 在兔中局部给药后测定房水中OMDI和OMD浓度以评估药代动力学。
- 在正常眼压兔、犬以及正常眼压和高眼压猴中评估OMDI的降眼压效应。
主要发现
- OMD为选择性EP2受体激动剂。
- OMDI对EP1结合较弱,但功能试验未显示其对EP1的激动活性。
- 局部给予OMDI后,房水中检测到OMD而未检测到OMDI。
- OMDI在正常眼压和高眼压动物中均显著降低眼压。
- OMDI单次和重复给药均显示显著降眼压效应,其有效持续时间提示每日一次给药可提供足够疗效。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The objective of this study was to investigate the pharmacologic characteristics of omidenepag isopropyl (OMDI), a compound developed as a novel intraocular pressure (IOP)-lowering agent, with better IOP control and fewer side effects than other prostanoid receptor agonists such as prostaglandin F receptor (FP) agonists. METHODS: Binding activities of OMDI and its hydrolyzed form, omidenepag (OMD), to human recombinant prostanoid receptors (DP1-2, EP1-4, FP, and IP) were evaluated. Based on these binding assays, the agonistic activities of OMDI and OMD were further evaluated using cultured cells expressing selected prostanoid receptors. The pharmacokinetics of OMDI after topical administration was assessed in rabbits by measurement of the concentrations of both OMDI and OMD in aqueous humor. The ocular hypotensive effect of OMDI was evaluated in ocular normotensive rabbits, dogs, and both ocular normotensive and hypertensive monkeys. RESULTS: OMD was determined to be a selective EP2 receptor agonist. OMDI weakly bound to EP1; however, the agonistic activity of OMDI to this receptor was not demonstrated in the functional assay. After topical administration of OMDI, OMD was detected in aqueous humor whereas OMDI was not detectable. OMDI significantly lowered IOP in both ocular normotensive and hypertensive animals. The significant ocular hypotensive effects of OMDI were demonstrated by both single and repeated dosing, and its effective duration suggests sufficient efficacy by once-daily dosing. CONCLUSIONS: These studies demonstrated that OMDI is hydrolyzed in the eye to OMD, an EP2 receptor agonist, with a significant ocular hypotensive effect in both ocular normotensive and hypertensive animal models.
引用
- Kirihara T, Taniguchi T, Yamamura K, et al. Pharmacologic Characterization of Omidenepag Isopropyl, a Novel Selective EP2 Receptor Agonist, as an Ocular Hypotensive Agent. Invest Ophthalmol Vis Sci. 2018. PMID: 29332128. doi:10.1167/iovs.17-22745
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。